Information  X 
Enter a valid email address

Faron Pharma OY Ord NPV (DI) (FARN)

Date Time Source Announcement
22 Jun 2021 7:00 am
RNS
Updated corporate presentation
14 Jun 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Bexmarilimab granted key US patent
03 Jun 2021 7:00 am
RNS
Bexmarilimab results published in CCR
17 May 2021 7:00 am
RNS
Bexmarilimab shows promising anti-tumour activity
14 May 2021 7:00 am
RNS
US rights to patent related to Traumakine
10 May 2021 2:30 pm
RNS
Holding(s) in Company
29 Apr 2021 12:45 pm
RNS
Grant of options
23 Apr 2021 1:45 pm
RNS
Board Change
  1:45 pm
RNS
Result of AGM
29 Mar 2021 7:00 am
RNS
Appointment of a Broker
25 Mar 2021 7:45 am
RNS
Exercise of Options
  7:30 am
RNS
Notice of Faron Pharmaceuticals Ltd's AGM
  7:15 am
RNS
Faron?s Annual Report 2020 published
  7:00 am
RNS
Financial statement January 1 to December 31 2020
22 Mar 2021 7:00 am
RNS
Bexmarilimab (Clevegen) development update
11 Mar 2021 7:00 am
RNS
Faron to Present at Oppenheimer Conference
02 Mar 2021 7:00 am
RNS
Faron to Present at H.C. Wainwright Conference
25 Feb 2021 7:00 am
RNS
Notice of Full-Year Results and Annual Report
17 Feb 2021 4:30 pm
RNS
Holding(s) in Company
12 Feb 2021 3:00 pm
RNS
Registration of Placing Shares
  7:00 am
RNS
Results of Placing and Issue Price
11 Feb 2021 4:30 pm
RNS
Proposed Issue and Placing of Shares
26 Jan 2021 7:00 am
RNS
Update on TRAUMAKINE development
20 Jan 2021 2:06 pm
RNS
Second Price Monitoring Extn
  2:01 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
Bexmarilimab (Clevegen) development update
18 Jan 2021 2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
  11:06 am
RNS
Second Price Monitoring Extn
  11:01 am
RNS
Price Monitoring Extension
  7:00 am
RNS
US Department of Defense to support TRAUMAKINE
04 Jan 2021 7:00 am
RNS
Faron to Present at H.C. Wainwright
21 Dec 2020 7:00 am
RNS
Faron's financial calendar for 2021
10 Dec 2020 7:00 am
RNS
Presents at ESMO Immuno-Oncology Virtual Congress
23 Nov 2020 7:30 am
RNS
To Participate in Upcoming Investor Conferences
  7:00 am
RNS
Bexmarilimab (Clevegen) development update
20 Nov 2020 7:00 am
RNS
Issue of Equity
16 Oct 2020 11:35 am
RNS
First Results from WHO Solidarity Trial
14 Oct 2020 2:15 pm
RNS
Grant of options
30 Sep 2020 9:45 am
RNS
Holding(s) in Company
24 Sep 2020 7:15 am
RNS
Exercise of options
  7:00 am
RNS
Half-year Report
18 Sep 2020 7:00 am
RNS
MATINS trial data presented at ESMO
09 Sep 2020 12:00 pm
RNS
Faron to Present at H.C. Wainwright Conference
27 Aug 2020 7:00 am
RNS
Notice of Half-Year Report
18 Aug 2020 7:00 am
RNS
Traumakine Update
17 Aug 2020 4:41 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
27 Jul 2020 7:00 am
RNS
Change of Adviser
20 Jul 2020 4:41 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
08 Jul 2020 3:00 pm
RNS
Managers' transactions
16 Jun 2020 7:01 am
RNS
Faron hosts virtual R&D Day today
  7:00 am
RNS
Faron update on pipeline progress ahead of R&D Day
15 Jun 2020 7:00 am
RNS
Faron receives EUR 2.1 million funding from BF
11 Jun 2020 7:00 am
RNS
Faron selected for EUR2.5 million grant from EIC
01 Jun 2020 7:00 am
RNS
MATINS Update
28 May 2020 7:00 am
RNS
Faron announces R&D Day to be held in June
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t